Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities

Annual Review of Pharmacology and Toxicology

Volumn 58, Issue , 2018, Pages 411-428

  Pfau, Madeline L ^a   Ménard, Caroline ^a   Russo, Scott J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

inflammation; major depressive disorder; microbiome; mood disorders; therapeutics

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIBODY; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; ETANERCEPT; GLIBENCLAMIDE; IMIPRAMINE; INFLIXIMAB; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; PROPRANOLOL; QUINOLINIC ACID; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIRUKUMAB; TOCILIZUMAB; YOGHURT; AUTACOID;

ANTIDEPRESSANT ACTIVITY; ASTROCYTE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; GLIA; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; MEDIATOR; MENTAL PATIENT; MICROBIOME; MICROGLIA; MONOCYTE; MOOD DISORDER; NEUTROPHIL; NONHUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PSYCHONEUROIMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; REWARD; TREATMENT RESISTANT DEPRESSION; ANIMAL; BRAIN; METABOLISM;

ANIMALS; BRAIN; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOOD DISORDERS;

EID: 85040564849     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010617-052823     Document Type: Review

References (0)